NFE2L2 and Kaposi's sarcoma: Our report points out Nrf2 and its associated factors as a putative pharmacological target for controlling cell growth in cells transformed by KSHV oncogenes providing the basis to focus our efforts in considering Nrf2 and associated proteins as therapeutic targets in KS treatment.